Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients

Neuropsychobiology. 2001;43(4):273-6. doi: 10.1159/000054902.


The effects of a 5-day treatment with rivastigmine on the resting EEG power spectrum were studied in 15 mildly to moderately ill Alzheimer patients. In these patients, beta power was positively correlated with cognitive performance and negatively correlated with functional impairment. Rivastigmine produced a decrease in delta and theta power with no effect of hemisphere and electrode position. Delta power decrease reflects the cerebral cholinergic action of rivastigmine and may thus allow a quantitative assessment of its CNS effects.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / physiopathology*
  • Carbamates / therapeutic use*
  • Cholinesterase Inhibitors / therapeutic use*
  • Electroencephalography / drug effects*
  • Female
  • Humans
  • Male
  • Neuroprotective Agents / therapeutic use*
  • Phenylcarbamates*
  • Psychiatric Status Rating Scales
  • Rivastigmine


  • Carbamates
  • Cholinesterase Inhibitors
  • Neuroprotective Agents
  • Phenylcarbamates
  • Rivastigmine